Company intelligence / Profile preview

Aimei Weixin Biopharmaceutical

Ownership: Private
Employees: ~500
Development stage: Other

Overview

AIM Weixin Biopharmaceutical is a leading Chinese biotechnology company specializing in the research, development, and manufacturing of human vaccines. As a core subsidiary of AIM Vaccine, the company operates large-scale production facilities and maintains a robust pipeline of preventative biologics. Its commercial portfolio includes widely used vaccines for rabies and hepatitis B, while its R&D efforts focus on next-generation mRNA and recombinant protein technologies. The company plays a critical role in China's public health infrastructure by providing high-quality, domestically produced immunization solutions.

Therapeutic areas: Infectious Diseases
Modalities: VaccinemRNA-based drugsRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Aimei Weixin Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aimei Weixin Biopharmaceutical.

Explore the full profile